All In Biotech

Drug Trial Radar · NCT00091819

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus

Last checked: Nov 20, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 862 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

862

Actual

Start

Jan 2005

Primary completion

Jun 2006

Study completion Jun 2006

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 21, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.

Conditions

  • Staphylococcal Skin Infection

Interventions

  • TelavancinDrug

    Telavancin 10 mg/kg/day, IV for up to 14 days.

  • VancomycinDrug

    Vancomycin 1 Gm IV q 12 hrs for up to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical ResponseTime frame: 7-14 days following end of antibiotic treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Paradise Valley Hospital, 2400 E. 4th Street

    National City, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.